Zheng Yu, Trivedi Trupti, Lin Ruby Cy, Fong-Yee Colette, Nolte Rick, Manibo Jeline, Chen Yunzhao, Hossain Musharraf, Horas Konstantin, Dunstan Colin, Zhou Hong, Seibel Markus J
Bone Research Program, ANZAC Research Institute, Sydney, New South Wales, Australia.
Asbestos Diseases Research Institute, Cardiothoracic Genomics, Sydney, New South Wales, Australia.
Bone Res. 2017 Sep 5;5:17023. doi: 10.1038/boneres.2017.23. eCollection 2017.
Vitamin D co-regulates cell proliferation, differentiation and apoptosis in numerous tissues, including cancers. The known anti-proliferative and pro-apoptotic actions of the active metabolite of vitamin D, 1,25-dihydroxy-vitamin D [1,25(OH)D] are mediated through binding to the vitamin D receptor (VDR). Here, we report on the unexpected finding that stable knockdown of VDR expression in the human breast and prostate cancer cell lines, MDA-MB-231 and PC3, strongly induces cell apoptosis and inhibits cell proliferation Implantation of these VDR knockdown cells into the mammary fat pad (MDA-MB-231), subcutaneously (PC3) or intra-tibially (both cell lines) in immune-incompetent nude mice resulted in reduced tumor growth associated with increased apoptosis and reduced cell proliferation compared with controls. These growth-retarding effects of VDR knockdown occur in the presence and absence of vitamin D and are independent of whether cells were grown in bone or soft tissues. Transcriptome analysis of VDR knockdown and non-target control cell lines demonstrated that loss of the VDR was associated with significant attenuation in the Wnt/β-catenin signaling pathway. In particular, cytoplasmic and nuclear β-catenin protein levels were reduced with a corresponding downregulation of downstream genes such as Axin2, Cyclin D1, interleukin-6 (IL-6), and IL-8. Stabilization of β-catenin using the GSK-3β inhibitor BIO partly reversed the growth-retarding effects of VDR knockdown. Our results indicate that the unliganded VDR possesses hitherto unknown functions to promote breast and prostate cancer growth, which appear to be operational not only within but also outside the bone environment. These novel functions contrast with the known anti-proliferative nuclear actions of the liganded VDR and may represent targets for new diagnostic and therapeutic approaches in breast and prostate cancer.
维生素D在包括癌症在内的众多组织中共同调节细胞增殖、分化和凋亡。维生素D的活性代谢物1,25-二羟基维生素D [1,25(OH)D] 已知的抗增殖和促凋亡作用是通过与维生素D受体 (VDR) 结合来介导的。在此,我们报告了一个意外发现:在人乳腺癌和前列腺癌细胞系MDA-MB-231和PC3中稳定敲低VDR表达,强烈诱导细胞凋亡并抑制细胞增殖。将这些VDR敲低的细胞植入免疫缺陷裸鼠的乳腺脂肪垫 (MDA-MB-231)、皮下 (PC3) 或胫骨内 (两种细胞系),与对照相比,肿瘤生长减少,同时凋亡增加,细胞增殖减少。VDR敲低的这些生长抑制作用在有或没有维生素D的情况下都会出现,并且与细胞是在骨组织还是软组织中生长无关。对VDR敲低和非靶向对照细胞系的转录组分析表明,VDR的缺失与Wnt/β-连环蛋白信号通路的显著减弱有关。特别是,细胞质和细胞核中的β-连环蛋白蛋白水平降低,同时下游基因如Axin2、细胞周期蛋白D1、白细胞介素-6 (IL-6) 和IL-8相应下调。使用GSK-3β抑制剂BIO稳定β-连环蛋白部分逆转了VDR敲低的生长抑制作用。我们的结果表明,未结合配体的VDR具有迄今未知的促进乳腺癌和前列腺癌生长的功能,这些功能似乎不仅在骨环境内而且在骨环境外都起作用。这些新功能与已知的结合配体的VDR的抗增殖核作用形成对比,可能代表乳腺癌和前列腺癌新诊断和治疗方法的靶点。